How to Develop an Effective Pharmaceutical Contamination Control Strategy

Upcoming

Virtual Learning
January 24, 2023

7.25 hrs VILT, 0.5 hrs self-paced

1 day

Register
Virtual Learning
June 20, 2023

7.25 hrs VILT, 0.5 hrs self-paced

1 day

Register

About This Course

International regulators and industry experts agree that the most economic and effective way of assuring the sterility of your products is through a contamination control strategy. This interactive one-day course takes a deep dive into how you can develop a contamination control strategy to help you mitigate risk and improve product quality.

How can you ensure that your strategy for contamination control meets the requirements of EU GMP Volume 4 Annex 1 and helps you to drive down quality risk, non-compliance and waste? Join us on this course to gain insight into how to generate an end-to-end pharmaceutical contamination control strategy that balances precautions to risk.

If you choose our virtual learning option, training will be delivered via a combination of live instructor-led virtual classrooms and self-paced online learning. Full details will be sent to you following registration.

Purpose of the Course

The contamination control strategy (CCS) is a document that identifies and assesses risk, explores the mitigating options and defines the preventive actions that may be associated with the full range of sources of viable contamination of sterile products. This document consolidates all the measures found in the pharma quality system that contribute to sterility assurance and evaluates their effectiveness and resilience.

Preparing, evaluating and deploying the CCS is a key step in meeting cGMP and providing effective sterility assurance. This course provides practical guidance and examples so that your CCS is proactive and comprehensive in its approach.

Key Learning Objectives

On completion of this contamination control strategy course delegates will know and understand:

  • An overview of changes in the new Annex 1 as well as their implications and how to interpret them
  • Team creation, methodology, format and content in preparing the CCS (we provide a detailed guide)
  • Expectations of regulatory bodies regarding the CCS and how they will use it to assess compliance with the cGMP of your sterile facility

Who Should Attend

QA, production, microbiology and technical services professionals and anyone tasked with reducing the common risks in sterile production.

Course Tutors

Course tutors will be selected from the following:

Richard Funnell - Richard spent 11 years with the MHRA, including seven as a Senior GMP Inspector with the lead for IMPs. Richard has special expertise in the knowledge of sterile manufacture and the manufacture of IMPs. Richard also spent seventeen years within a large pharmaceutical manufacturer in a variety of production and QA roles, including the manufacture of tablets, oral liquids, and sterile products (including aseptically filled lyophilised vials).

James Culyer - James is a Quality Consultant and Qualified Person with over 20 years of experience in technical, quality and managerial roles within parenteral, non-sterile liquid, oral solid dosage, and inhalation product manufacture. He has extensive experience managing all aspects of manufacturing-site quality management systems and is a specialist in global supply chain assurance activities. He has practical experience with a wide range of medicinal product dosage forms — tablets, capsules, powders, sterile injections (large-volume parenterals, vials, ampoules), transdermal patches, oral non-sterile liquids, inhalation products (pMDIs), and creams and ointments.